Hyperthermic pelvic perfusion with tumor necrosis factor-α for locally advanced cancers: Encouraging results of a phase II study

Annals of Surgery

Volumn 255, Issue 2, 2012, Pages 281-286

  Bonvalot, Sylvie ^a   De Baere, Thierry ^a   Mendiboure, Jean ^a   Paci, Angelo ^a   Farace, Françoise ^a   Drouard Troalen, Laurence ^a   Bonnet, Laure ^a   Hakime, Antoine ^a   Bonniaud, Guillaume ^a   Raynard, Bruno ^a   Israel, Philippe ^a   Le Cesne, Axel ^a   Eggermont, Alexander M ^a   Laplanche, Agnès ^a   Muret, Jane ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MELPHALAN; TASONERMIN; TECHNETIUM 99M; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ADVANCED CANCER; AMPUTATION; AREA UNDER THE CURVE; ARTICLE; CANCER GROWTH; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER SURVIVAL; CANCER THERAPY; CARCINOMA; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; ENDOCRINE TUMOR; EVISCERATION; FEMALE; FOLLOW UP; HEART RATE; HUMAN; HYPERTHERMIC THERAPY; ISOLATED PELVIC PERFUSION; MALE; MAXIMUM PLASMA CONCENTRATION; MELANOMA; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN PERFUSION; OVERALL SURVIVAL; PELVIS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; TOURNIQUET; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DISEASE-FREE SURVIVAL; ENDOCRINE GLAND NEOPLASMS; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; MELANOMA; MELPHALAN; MIDDLE AGED; PELVIC NEOPLASMS; RECURRENCE; SARCOMA; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84855826010     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e318242ebe7     Document Type: Article

References (33)

1. Gannon CJ, Zager JS, Chang GJ, et al. Pelvic exenteration affords safe and durable treatment for locally advanced rectal carcinoma. Ann Surg Oncol. 2007;14:1870-1877. (Pubitemid 46870946)
2. Ḧockel M, Dornḧofer N. Pelvic exenteration for gynaecological tumours: achievements and unanswered questions. Lancet Oncol. 2006;7:837-847. (Pubitemid 44464077)
3. Creech O, Krementz ET, Ryan RF, et al. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg. 1958;148:616-632.
4. Eggermont AM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg. 1996;224:756-764.
5. Bonvalot S, Rimareix F, Causeret S, et al. Hyperthermic isolated limb perfusion in locally advanced soft tissue sarcoma and progressive desmoid-type fibromatosis with TNF 1 mg and melphalan (T1-M HILP) is safe and efficient. Ann Surg Oncol. 2009;16:3350-3357.
6. Rossi CR, Pasquali S, Mocellin S, et al. Long-term results of melphalan-based isolated limb perfusion with or without low-dose TNF for in-transit melanoma metastases. Ann Surg Oncol. 2010;17:3000-3007.
7. Wile AG, Stemmer EA, Andrews PA, et al. Pharmacokinetics of 5-fluorouracil during hyperthermic pelvic isolation-perfusion. J Clin Oncol. 1985;3:849-852. (Pubitemid 15062913)
8. Belliveau JF, Wanebo HJ. Clinical pharmacokinetics of isolated pelvic perfusion. Surg Oncol Clin N Am. 2008;17:773-784.
9. van Ijken MG, van Etten B, Guetens G, et al. Balloon catheter hypoxic pelvic perfusion with mitomycin C and melphalan for locally advanced tumours in the pelvic region: a phase I-II trial. Eur J Surg Oncol. 2005;31:897-904. (Pubitemid 41435260)
10. Pilati P, Mocellin S, Miotto D, et al. Stop-flow technique for loco-regional delivery of antiblastic agents: literature review and personal experience. Eur J Surg Oncol. 2002;28:544-553. (Pubitemid 35446785)
11. Wanebo HJ, DiSiena M, Begossi G, et al. Isolated chemotherapeutic perfusion of pelvis as neoadjuvant or palliative therapy for advanced cancer of the rectum. Ann Surg Oncol. 2008;15:1107-1116.
12. Guadagni S, Fiorentini G, Palumbo G, et al. Hypoxic pelvic perfusion with mitomycin C using a simplified balloon-occlusion technique in the treatment of patients with unresectable locally recurrent rectal cancer. Arch Surg. 2001;136:105-112. (Pubitemid 32064130)
13. De Wilt JH, Manusama ER, van Tiel ST, et al. Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer. 1999;80:161-166. (Pubitemid 29210102)
14. Lejeune FJ, Líenard D,MatterM, et al. Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun. 2006;6:6.
15. Bonvalot S, Laplanche A, Lejeune F, et al. Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better? Ann Oncol. 2005;16:1061-1068. (Pubitemid 41418306)
16. Bonvalot S, Bonnay M, Drouard-Troalen L, et al. Pressure-suit combined with pelvic stop-flow: a feasibility study in a bovine model. Eur J Surg Oncol. 2007;33:114-118. (Pubitemid 46131874)
17. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: World Health Organization; 1979. WHO offset publication No. 48.
18. Barker WC, Andrich MP, Alexander HR, et al. Continuous intraoperative external monitoring of perfusate leak using iodine-131 human serum albumin during isolated perfusion of the liver and limbs. Eur J Nucl Med. 1995;22:1242-1248.
19. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216. (Pubitemid 30099779)
20. Simon R. Optimal two-stage designs for phase II clinical trials in oncology. Controlled Clin Trials. 1989;10:1-10. (Pubitemid 19099520)
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc. 1958;53:457-481.
22. Rothman KJ. Estimation of confidence limits for the cumulative probability of survival in life table analysis. J Chron Dis. 1978;31:557-560. (Pubitemid 9027411)
23. Fotopoulou C, Neumann U, Kraetschell R, et al. Long-term clinical outcome of pelvic exenteration in patients with advanced gynecological malignancies. J Surg Oncol. 2010;101:507-512.
24. Gregorc V, Zucali PA, Santoro A, et al. Phase II study of asparagine-glycinearginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. J Clin Oncol. 2010;28:2604-2811.
25. Creagan ET, Kovach JS, Moertel CG, et al. A phase I clinical trial of recombinant human tumor necrosis factor. Cancer. 1988;62:2467-2471. (Pubitemid 19006423)
26. Roberts MS, Wu ZY, Siebert GA, et al. Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy. Melanoma Res. 2001;11:423-431. (Pubitemid 32735234)
27. Guadagni S, SantinamiM, Patuzzo R, et al. Hypoxic pelvic and limb perfusion with melphalan and mitomycin C for recurrent limb melanoma: a pilot study. Melanoma Res. 2003;13:51-58. (Pubitemid 36269814)
28. McMahon N, Cheng TY, Beasley GM, et al. Optimizing melphalan pharmacokinetics in regionalmelanoma therapy: does correcting for ideal body weight alter regional response or toxicity? Ann Surg Oncol. 2009;16:953-961.
29. Belliveau JF, Arevalo E, Griffin H, et al. Isolated pelvic perfusion: plasma pharmacokinetics depend primarily on drug dosage and not the type of drug. Cancer Chemother Pharmacol. 2005;55:318-322. (Pubitemid 40379254)
30. van IJken MG, de Bruijn EA, ten Hagen TL, et al. Balloon catheter hypoxic abdominal and pelvic perfusion with tumour necrosis factor-alpha, melphalan and mitomycin C: a pharmacokinetic study in pigs. Eur J Surg Oncol. 2004;30:699-707.
31. Desar IM, van Herpen CM, van Laarhoven HW, et al. Beyond RECIST:molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat Rev. 2009;35:309-321.
32. Bruix J, Sherman M, Llovet JM, et al. EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421-430. (Pubitemid 32844200)
33. El-Maraghi RH, Eisenhauer EA. Reviewof phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III. J Clin Oncol. 2008;26:1346-1354.